These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 26573178)

  • 1. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.
    Ehsan Z; Clancy JP
    Future Microbiol; 2015; 10(12):1901-12. PubMed ID: 26573178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Ehsan Z; Wetzel JD; Clancy JP
    Expert Opin Investig Drugs; 2014 May; 23(5):743-9. PubMed ID: 24597573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
    Meers P; Neville M; Malinin V; Scotto AW; Sardaryan G; Kurumunda R; Mackinson C; James G; Fisher S; Perkins WR
    J Antimicrob Chemother; 2008 Apr; 61(4):859-68. PubMed ID: 18305202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled liposomal amikacin.
    Waters V; Ratjen F
    Expert Rev Respir Med; 2014 Aug; 8(4):401-9. PubMed ID: 24882271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Bilton D; Pressler T; Fajac I; Clancy JP; Sands D; Minic P; Cipolli M; Galeva I; Solé A; Quittner AL; Liu K; McGinnis JP; Eagle G; Gupta R; Konstan MW;
    J Cyst Fibros; 2020 Mar; 19(2):284-291. PubMed ID: 31451351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel amikacin inhaled formulation for the treatment of lower respiratory tract infections.
    Antoniu S; Azoicai D
    Drugs Today (Barc); 2013 Nov; 49(11):683-92. PubMed ID: 24308015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.
    Clancy JP; Dupont L; Konstan MW; Billings J; Fustik S; Goss CH; Lymp J; Minic P; Quittner AL; Rubenstein RC; Young KR; Saiman L; Burns JL; Govan JR; Ramsey B; Gupta R;
    Thorax; 2013 Sep; 68(9):818-25. PubMed ID: 23749840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Joint Intratracheal Surfactant-Antibacterial Therapy in Experimental Pseudomonas-Induced Pneumonia.
    Birkun AA; Kubyshkin AV; Novikov NY; Krivorutchenko YL; Fedosov MI; Postnikova ON; Snitser AA
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):299-307. PubMed ID: 25517041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
    Ballmann M; Smyth A; Geller DE
    Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerosolized antibiotics in cystic fibrosis: an update.
    Fiel SB
    Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Høiby N
    BMC Med; 2011 Apr; 9():32. PubMed ID: 21463524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.
    Moore JE; Mastoridis P
    J Clin Pharm Ther; 2017 Jun; 42(3):259-267. PubMed ID: 28374433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.
    Okusanya OO; Bhavnani SM; Hammel JP; Forrest A; Bulik CC; Ambrose PG; Gupta R
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5005-15. PubMed ID: 24687506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
    Antonela Antoniu S
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Assael BM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.